Aura Biosciences, Inc. — Director's Dealing 2021

Nov 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aura Biosciences, Inc. (AURA)
CIK: 0001501796
Period of Report: 2021-11-02

Reporting Person: Matrix Capital Management Company, LP (10% Owner)
Reporting Person: GOEL DAVID E. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-02	Common Stock, par value $0.00001 per share ("Common Stock")	C	2327870	—	Acquired	2327870	Indirect
2021-11-02	Common Stock	P	1785000	$14	Acquired	4112870	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-02	Series E Convertible Preferred Stock	$	C	2327870	Disposed		Common Stock (2327870)	Indirect

Footnotes

F1: The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F2: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.